SELLAS Life Sciences shares plunged nearly 20% after the biotechnology company priced a $150 million public offering at $13 per share, a discount of around 28% to its previous close. The sell-off followed a sharp rally triggered by positive Phase 3 REGAL trial results for its experimental leukemia vaccine.
Read full article